NAMs Technology Partn3Ring webinar series

Icons representing collaboration and new approach methodologies.

Our Technology Partn3Ring webinars showcase technologies with 3Rs potential to the wider scientific community to identify new partners for further development, qualification and use. Webinars consist of short pitches outlining the 3Rs technologies and unique opportunities for collaboration.

The next Technology Partn3Ring webinar topic will be delivered as a fortnightly webinar series between April and July 2026, reflecting the interest from researchers and technology developers working in new approach methodologies (NAMs), which are replacement technologies for use in assessing chemical or drug toxicity.

The series is open to researchers, clinicians, pharmaceutical and industry professionals. Audience members will be able to ask questions to the speakers and connect with the speakers to access unique collaboration opportunities.

Upcoming webinars

Register for session 2: Wednesday 6 May, 14.00 – 15.15 (BST)

The second NAMs session will include presentations from researchers working across human relevant in vitro technologies, ranging from brain tumour modelling, stem cell platforms in toxicity and imaging, cell-based assays in safety assessment and organ function studies.

From screening to safety: Advancing the Membrane Proteome Array for human-relevant off-target risk assessment of biotherapeutics
Jonathan Richards (Integral Molecular)

Human-relevant membrane proteome array to assess off-target binding of antibody-based therapies early in development.
Seeking new users and applications of the technology to expand 3Rs benefits.

Neural spheroid platform to model brain tumour migration and infiltration
Davide Danovi (Migration Biotherapeutics)

Human iPSC-based neural spheroid platform modelling tumour-brain interactions in glioblastoma.
Looking for collaborators to further develop the model and quantify cancer cell migration.

Cell-based assays for next generation development and quality control of Clostridial medicines
Ciara Doran (Sansanima Limited)

Non-animal, cell‑based assays for safety and potency testing of Clostridials.
Seeking partners for quality, process control or next generation development of botulinum toxin.

Catching stem cell-toxic drugs before they cause chronic organ failure
James L. Sherley (Asymmetrex® LLC)

Rapid, accurate counting and monitoring of tissue stem cells in heterogeneous tissue cell preparations used in in vitro drug toxicity assessment.
Seeking collaborators to help assess predictive value of technology in drug candidates known to cause chronic organ failure.

iPSC-derived multicellular miniorgans with advanced fluorescent sensor options
Jiwu Wang (Allele Biotechnology)

Bioprinted iPSC derived liver mini-organs to replace in vivo organ function studies in drug development.
Seeking teams with liver specific assay expertise to further qualify the model in longitudinal studies.

Register for session 3: Wednesday 20 May, 14.00 – 15.15 (BST)

The third NAMs session will include presentations from researchers working across in vitro models to replace the use of animals in bone, liver, heart and lung assays.

An MPS assay for human oral bioavailability: Seeking partners to accelerate assay validation
Yassen Abbas (CN-Bio Innovations)

CN-BIO Innovations develop microphysiological systems (MPS) models for drug discovery and development including liver, lung, multi-organ and immune competent models.
Looking for partners to help further qualify the models across use cases with a particular focus on new drug modalities.

Precision in motion: Functional human models for the future of drug safety
Erika Ferrari (BiomimX)

BiomimX have developed uHeart, a model of functional beating human cardiac tissue for cardiotoxicity and safety testing.
Seeking scientific partners to expand model validation (e.g. relevant cell providers) and partners to co-develop bespoke models for drug testing.

In vitro modelling of human osteoarthritis and tissue innervation
Abbas Ishaq (Alcyomics)

Alcyomics have developed a human osteochondral ex vivo model, generated from primary mesenchymal stem cells with the ability to include innervation and induce an osteoarthritic disease phenotype.
Looking for collaborators to further qualify their model, with the aim of establishing it as a robust translational platform for compound screening and therapeutic development.

Title TBC
Vinit Pereira (ImmuONE)

ImmuONE have developed morph_ONE, a high-content imaging-based safety screening tool designed to detect direct exposure and off-target toxicities in the lung.
Seeking end users to apply morph_ONE as a Tier 1 lung safety screening approach, enabling early identification of direct exposure off-target toxicities.

Recordings

Recordings of sessions will be available to re-watch on this page shortly after the session along with contact details should you wish to collaborate with the speaker. They will remain live for 12 months after the date of the recording.

Session 1: Wednesday 22 April 2026
The first NAMs webinar included presentations from four researchers working across invertebrate models as partial replacements for the use of mammals, human-relevant microphysiological models, drug efficacy and drug/consumer product toxicity testing.

Session 1: Wednesday 22 April 2026

The first NAMs webinar included presentations from four researchers working across invertebrate models as partial replacements for the use of mammals, human-relevant microphysiological models, drug efficacy and drug/consumer product toxicity testing.

Early drug screening with C. elegans: A 3Rs-aligned approach
Karthik Mohanraj (Magnitude Biosciences Limited)

High-throughput C. elegans platform, delivering scalable and predictive insights on drug efficacy, safety and mechanism of action.
Seeking collaborators to further qualify screening platform and provide access to comparator datasets.

Connect with Karthik for more information about their collaboration opportunity: karthik@magnitudebiosciences.com.

From model to method: Validating C. elegans-based DART assay towards regulatory use
Matteo Cornaglia (Nagi Bioscience)

Providing human relevant whole organism toxicity data that can replace early mammalian screens.
Seeking collaborators for new toxicology use cases, cross‑species comparison, and standardisation towards regulatory readiness.

Connect with Matteo for more information about their collaboration opportunity: matteo.cornaglia@nagibio.ch.

Neuromuscular junction-on-a-chip: Human based assays for toxin testing and drug development aligned with FDA and NAMs regulations
Margaret Magdesian (Ananda Devices)

Developing human iPSC‑based neuro and neuromuscular assays towards replacing animal use in neurotoxicity assays.
Seeking partners to benchmark and expand applications, including exploring incorporation into regulatory workflows.

Connect with Margaret for more information about their collaboration opportunity: margaret@anandadevices.com.

PEVITAC: Live invertebrate models for 3Rs research
Vitaliy Khutoryanskiy (University of Reading)

Developing invertebrate assays that can replace early-stage mammalian studies in toxicity, irritation, infection and formulation screening.
Seeking collaborators interested in co-developing and qualifying the invertebrate-based assays for broader application and increased translational relevance.

Connect with Vitaliy for more information about their collaboration opportunity: v.khutoryanskiy@reading.ac.uk.

NAMs Technology Partn3Ring webinar series

On this page:

Upcoming dates, open for registration

Future dates, subject to speaker availability:

Upcoming webinars

Register for session 2: Wednesday 6 May, 14.00 – 15.15 (BST)

Register for session 3: Wednesday 20 May, 14.00 – 15.15 (BST)

Recordings

Session 1: Wednesday 22 April 2026